No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
1 |
rs1656369 |
chr3:158280085-158280086 |
Enhancers Weak transcription
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
2 |
rs543639399 |
chr3:158280087-158280088 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
3 |
rs184587234 |
chr3:158280109-158280110 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
4 |
rs149021457 |
chr3:158280127-158280128 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
5 |
rs142067541 |
chr3:158280133-158280134 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
6 |
rs151324183 |
chr3:158280203-158280204 |
Flanking Active TSS Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
7 |
rs545967060 |
chr3:158280206-158280207 |
Flanking Active TSS Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
8 |
rs527671571 |
chr3:158280229-158280230 |
Flanking Active TSS Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
9 |
rs114679435 |
chr3:158280249-158280250 |
Flanking Active TSS Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
10 |
rs111486275 |
chr3:158280312-158280313 |
Flanking Active TSS Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
11 |
rs561423781 |
chr3:158280502-158280503 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
12 |
rs35076982 |
chr3:158280538-158280539 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
13 |
rs188952601 |
chr3:158280587-158280588 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
14 |
rs549923094 |
chr3:158280593-158280594 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
15 |
rs181521884 |
chr3:158280600-158280601 |
Enhancers Flanking Active TSS Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
16 |
rs553583388 |
chr3:158280604-158280605 |
Flanking Active TSS Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
17 |
rs538320464 |
chr3:158280668-158280669 |
Flanking Active TSS Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
18 |
rs577388558 |
chr3:158280714-158280715 |
Flanking Active TSS Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
19 |
rs547067326 |
chr3:158280756-158280757 |
Flanking Active TSS Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
20 |
rs186698286 |
chr3:158280794-158280795 |
Flanking Active TSS Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
21 |
rs535860352 |
chr3:158280875-158280876 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
22 |
rs189571333 |
chr3:158280916-158280917 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
23 |
rs140653305 |
chr3:158280940-158280941 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
24 |
rs562835790 |
chr3:158280966-158280967 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
25 |
rs537250408 |
chr3:158280997-158280998 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
26 |
rs1656368 |
chr3:158281021-158281022 |
Enhancers Weak transcription
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
27 |
rs180924314 |
chr3:158281098-158281099 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
28 |
rs545554455 |
chr3:158281119-158281120 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
29 |
rs560376702 |
chr3:158281149-158281150 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
30 |
rs185797397 |
chr3:158281155-158281156 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
31 |
rs368214929 |
chr3:158281220-158281221 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
32 |
rs571375094 |
chr3:158281275-158281276 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
33 |
rs190960470 |
chr3:158281297-158281298 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
34 |
rs557278008 |
chr3:158281302-158281303 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
35 |
rs561635665 |
chr3:158281307-158281308 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
36 |
rs531851006 |
chr3:158281385-158281386 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
37 |
rs145778519 |
chr3:158281410-158281411 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
38 |
rs565881875 |
chr3:158281426-158281427 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
39 |
rs565166892 |
chr3:158281439-158281440 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
40 |
rs138386402 |
chr3:158281472-158281473 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
41 |
rs141359737 |
chr3:158281618-158281619 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
42 |
rs183148673 |
chr3:158281625-158281626 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
43 |
rs34629395 |
chr3:158281711-158281712 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
44 |
rs145028294 |
chr3:158281734-158281735 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
45 |
rs547831413 |
chr3:158281745-158281746 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
46 |
rs569946368 |
chr3:158281768-158281769 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
47 |
rs536190540 |
chr3:158281781-158281782 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
48 |
rs558867573 |
chr3:158281797-158281798 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
49 |
rs138813617 |
chr3:158281851-158281852 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
50 |
rs9834415 |
chr3:158281894-158281895 |
Enhancers Weak transcription
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|